Renaissance Technologies LLC Has $203,000 Stake in MediWound Ltd. (NASDAQ:MDWD)

Renaissance Technologies LLC reduced its stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) by 66.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,418 shares of the biopharmaceutical company's stock after selling 23,026 shares during the quarter. Renaissance Technologies LLC owned about 0.11% of MediWound worth $203,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of MDWD. R Squared Ltd purchased a new position in MediWound in the 4th quarter worth about $32,000. Russell Investments Group Ltd. lifted its holdings in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 1,162 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after buying an additional 739 shares during the last quarter. Barclays PLC lifted its holdings in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after buying an additional 8,449 shares during the last quarter. Finally, Legato Capital Management LLC lifted its holdings in MediWound by 12.0% in the 4th quarter. Legato Capital Management LLC now owns 43,753 shares of the biopharmaceutical company's stock worth $779,000 after purchasing an additional 4,681 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Stock Up 2.9%

NASDAQ:MDWD traded up $0.50 during trading hours on Monday, reaching $18.03. The company had a trading volume of 20,005 shares, compared to its average volume of 88,133. The stock has a 50-day moving average of $16.98 and a two-hundred day moving average of $17.48. MediWound Ltd. has a one year low of $12.78 and a one year high of $24.00. The firm has a market capitalization of $194.87 million, a PE ratio of -6.22 and a beta of 0.30.

MediWound (NASDAQ:MDWD - Get Free Report) last announced its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million for the quarter, compared to analysts' expectations of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the prior year, the business earned ($0.19) earnings per share. As a group, sell-side analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MDWD shares. Craig Hallum assumed coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price for the company. StockNews.com upgraded MediWound to a "sell" rating in a report on Friday, March 21st. HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of MediWound in a research report on Thursday, March 20th. Finally, Alliance Global Partners started coverage on MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $29.75.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.